SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

Critical Metals Corp. is trending due to news regarding an amended agreement to increase its ownership stake in the Tanbreez rare earth project in Greenland. The community is discussing the implications of this deal, particularly its potential impact on the company's valuation and future prospects, with some suggesting a possible US government stake. Investors are also weighing the connection to other rare earth and lithium plays, and assessing the potential for a significant squeeze.

Amarin Corp. Plc is a pharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. It focuses on the development and commercialization of Vascepa capsules. The company was founded by Geoffrey William Guy on March 1, 1989 and is headquartered in Dublin, Ireland.

Amarin Corp - ADR

Amarin is trending following news of trial updates and increased volume, leading to a surge past its 52-week high. Community members are actively speculating about a potential buyout and the implications of new partnerships. Discussions also revolve around the company's financial health and future growth prospects in the competitive pharmaceutical landscape.

MannKind Corp. is a biopharmaceutical company, which focuses on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. Its products and pipeline include Afrezza, Pediatric Afrezza, V-Go, Tyvaso DPI, MNKD-101, MNKD-201, MNKD-301, and MNKD-501. The company was founded by Alfred E. Mann on February 14, 1991 and is headquartered in Danbury, CT.

Mannkind Corp

Mannkind ($MNKD) is trending as investors anticipate several near-term catalysts, including potential FDA acceptance of its pediatric Afrezza application and the closing of the scPharmaceuticals acquisition. Community discussions revolve around upcoming revenue growth, pipeline advancements, and speculation on a potential buyout, with some highlighting the high short interest as fuel for a potential squeeze. Bullish sentiment is building around the long-term potential of Mannkind's drug portfolio in addressing unmet needs in diabetes and lung diseases.

TMC the metals co., Inc. is a deep-sea minerals exploration company focused on the collection and processing of polymetallic nodules found on the seafloor in international waters of the Clarion Clipperton Zone in the Pacific Ocean (CCZ). These nodules contain high grades of four metals (nickel, copper, cobalt, manganese) which can be used as (i) feedstock for battery cathode precursors (nickel, cobalt and manganese sulfates, or intermediate nickel-copper-cobalt matte) for electric vehicles (EV) and renewable energy storage markets, (ii) copper cathode for EV wiring, energy transmission and other applications and (iii) manganese silicate for manganese alloy production required for steel production. The company was founded in 2021 and is headquartered in Vancouver, Canada.

TMC the metals company Inc

TMC is trending as the community discusses potential catalysts, including government support and regulatory approvals, within the broader context of critical minerals and deep-sea mining. Community members are analyzing chart patterns, anticipating a breakout, and speculating on potential government deals. Discussions also include the potential impact of recent news in the sector.

eCash (XEC) is a Layer-1 digital cash network, developed by Bitcoin ABC. It was created on Nov 15th, 2020, and has since distinguished itself from its predecessors and other Bitcoin clients by integrating the breakthrough Avalanche consensus with its core proof-of-work (PoW) layer, extending its security and fundamental capabilities.  This hybrid consensus integration gives it unique properties for a Bitcoin-like chain, such as interoperability, staking rewards, real-time processing, and an improved overall extensibility, which is hard to achieve in a completely trustless manner using only Nakamoto consensus.  The development roadmap is set with three main goals: Scaling transaction throughput from ~100 tps to more than 5.000.000 tps Improving the payment experience with a less than 3 second transaction finality time Extending the protocol and establishing fork-free upgrade routines, allowing for more rapid, iterative development

eCash

eCash is trending due to discussions surrounding the Electronic Cash Conference (ECC) 2025 in Barcelona, where developers are exploring Bitcoin script's potential and new use cases. The community is also excited about recent developments, including new listings on Houdini Swap and updates to Local eCash, which are contributing to increased interest.

NXP Semiconductors NV is a holding company which engages in the provision of semiconductor solutions. It operates through the following geographical segments: China, Netherlands, United States, Singapore, Germany, Japan, South Korea, Malaysia, and Other Countries. The company was founded on August 2, 2006, and is headquartered in Eindhoven, the Netherlands.

NXP Semiconductors NV

NXPI is gaining attention, partly driven by unusual options activity suggesting potentially bearish sentiment among some traders. Community members are also discussing its exposure to the automotive chip market and potential benefits from the AI sector. Analysts are weighing in with updated ratings and price targets, contributing to the ongoing conversation.

What makes MOG an absolute game-changer is our relentless dedication to memes and viral brilliance! We don't settle for mediocrity; we plunge into the realm of sheer awesomeness! Our community is a powerhouse of meme warriors, unleashing an unstoppable onslaught of viral memes that'll leave you in awe and stitches!  We're not here to play games; we're here to dominate! MOG is all about pushing the boundaries, smashing through barriers, and leaving our competitors eating our dust! Our passion for humor burns like an inferno, and we won't rest until the entire internet bows down to our meme supremacy!  And our community? It's a brotherhood, an unyielding powerhouse of support and camaraderie! When you're part of MOG, you're part of an unstoppable force, a family forged by the fire of meme revolution!  So, if you're ready to be part of the most intense, mind-bending memecoin movement ever conceived, then buckle up, strap in, and brace yourself! MOG is here to claim the throne, and we're taking no prisoners! Get ready to witness meme history in the making!

 MOG Coin

MOG coin is trending as the community discusses potential price predictions and its place within the meme coin sector. Bullish sentiment is fueled by historical trends and anticipation of upcoming events, including potential FED rate cuts that could boost altcoins. Some traders are also closely watching for a break above the downtrend from July peak to confirm further upside.

Diamondback Energy, Inc. is an independent oil and natural gas company, which engages in the acquisition, development, exploration, and exploitation of unconventional, onshore oil, and natural gas reserves. It operates through the Upstream and Midstream Services segments. The Upstream segment focuses on the Permian Basin operations in West Texas. The Midstream Services segment is involved in the Midland and Delaware Basins. The company was founded in December 2007 and is headquartered in Midland, TX.

Diamondback Energy Inc

Diamondback Energy is trending amid discussions around production outlook, capital expenditure plans, and potential acquisitions, particularly following recent news of executive changes. Community members are actively weighing the company's financial health, dividend payouts, and strategic direction in the context of fluctuating oil prices and geopolitical factors. Speculation around buybacks and takeover potential is also contributing to the heightened interest.

Direxion Shares ETF Trust - Direxion Daily TSLA Bull 2X Shares

Direxion Daily TSLA Bull 2X Shares

TSLL is trending due to positive momentum in Tesla, with some traders eyeing it as a leveraged way to capture potential gains. Community members are actively discussing entry and exit points, with significant call option activity observed. Recent news around Tesla's robotaxi progress and potential market expansion is adding to the bullish sentiment.

Newsmax Inc. is a holding company, which engages in television broadcasting and multi-platform content publishing that produces original news and editorial content for consumers through various media outlets, including TV new channels, digital and print publications. It operates through the Broadcasting and Digital Segments. The Broadcasting segment produces and licenses news, business news and lifestyle content for distribution through both MVPDs and free OTT streaming platforms. The Digital segment is composed of Newsmax.com and affiliated websites. The company was founded by Christopher Ruddy in 1998 and is headquartered in Boca Raton, FL.

Newsmax Inc. - Ordinary Shares - Class B

Newsmax Inc

NMAX is trending as investors discuss unusual options activity and potential upside, with some highlighting LEAPS call options. Community members are sharing perspectives on the stock's overnight dips and potential catalysts, including its relationship to other Trump-related stocks and the broader media landscape. The stock is also being discussed in the context of political events and media budgets.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Will the FDA's Nod for Subcutaneous Keytruda Ease Merck's Headwinds?

FDA clears MRK's Keytruda Qlex, a subcutaneous option that promises faster treatment and new patent protection amid looming headwinds.

Retail traders kept a cautious stance on Summit Therapeutics on Tuesday after Barclays initiated coverage of the biotech with an ‘Underweight’ rating and a $13 price target.&nbsp;The stock fell 4.3% to $18.12 on Tuesday and slipped another 0.4% after hours.Barclays flagged a long regulatory path, stiff competition in lung cancer, and a rival backed by a major pharma partner as key risks.The brokerage said it still sees a “high likelihood” of approval for ivonescimab, Summit’s experimental bispecific antibody, but its models suggest only modest improvements over the current standard of care.&nbsp;The note contrasted with&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/summit-therapeutics-gets-40-dollar-price-target-from-guggenheim/chwdQXARdpT">Guggenheim’s initiation</a> earlier this month at ‘Buy’ with a $40 price target, which argued the company’s late-stage trials could offer multi-fold upside if successful.The cautious call comes just days after Summit presented&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/retail-traders-flock-to-summit-therapeutics-after-new-cancer-drug-data-shows-survival-gains/chwW19jRdqH">new follow-up data from its Phase III HARMONi trial</a> at the World Conference on Lung Cancer in Barcelona. Patients with advanced non-small cell lung cancer on ivonescimab plus chemotherapy lived a median of 16.8 months versus 14 months on chemo alone, with hazard ratios pointing to survival benefits across Western and Asian cohorts.&nbsp;Earlier results showed the study met its main goal, cutting the risk of progression or death by 48% compared with chemotherapy alone.Ivonescimab, licensed from China’s Akeso and already approved there as SMT112, has been tested in more than 2,800 patients worldwide and carries a U.S. FDA Fast Track designation.&nbsp;Summit is running additional late-stage trials, HARMONi-3 and HARMONi-7, comparing ivonescimab against Merck’s blockbuster PD-1 drug Keytruda in first-line lung cancer, with readouts expected between 2027 and 2028.On Stocktwits, retail sentiment was ‘bearish’ amid ‘low’ message volume.One user remarked that they would only consider buying Summit Therapeutics if it returned to penny-stock levels, calling it “another one added to the biotech graveyard.”<stembedurl>https://stocktwits.com/Jahlisgo/message/628908644</stembedurl>Another user said they were holding their shares following the updated brokerage reports, waiting for what they described as a future payday.<stembedurl>https://stocktwits.com/Reesh/message/628891775</stembedurl><a href="https://stocktwits.com/symbol/SMMT">Summit’s stock</a> has risen 1.5% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Propanc Biopharma (PPCB) tumbled 17% in after-hours trading on Monday, with activity surging to nearly 33,000 times its usual volume. (Photo credit: Getty Images)

Summit Therapeutics Stock Draws Cautious Retail Mood After Barclays ‘Underweight’ Call: ‘Added To The Biotech Graveyard’

Barclays set a $13 price target, citing a long regulatory path and stiff competition in lung cancer.

Equity

Merck Falls 14% YTD: Time to Buy, Sell or Hold the Stock?

Merck stock is down 14% this year as Keytruda-led growth gets offset by Gardasil weakness and looming patent risks, which cloud the outlook.

SMMT Stock Plummets 25% on Regional Data Differences in NSCLC Study

Summit Therapeutics plunges 25% after its HARMONi study shows sharp regional differences in lung cancer trial outcomes.

Retail traders turned their attention to Summit Therapeutics late Sunday after the company released new follow-up data from its Phase III HARMONi trial. The study is testing ivonescimab, an experimental cancer drug, together with chemotherapy in patients with advanced non-small cell lung cancer.The trial focused on people whose tumors carried Estimated Glomerular Filtration Rate (EGFR) mutations and who had already failed a third-generation EGFR therapy. In this group, past attempts with PD-1 drugs had not delivered survival gains.In fresh results presented at the World Conference on Lung Cancer in Barcelona, patients on ivonescimab plus chemotherapy lived longer on average than those on chemotherapy alone.&nbsp;The overall survival hazard ratio&nbsp;was 0.78,&nbsp;indicating an improvement from the earlier analysis. Median survival was 16.8 months with the drug compared to 14.0 months with chemotherapy.Among Western patients,&nbsp;the median overall survival&nbsp;was 17 months with ivonescimab versus 14 months for the placebo. In North America specifically, median overall survival had not yet been reached in the ivonescimab arm compared with 14 months on chemotherapy alone.&nbsp;Median survival in Asian patients was 16.7 months for ivonescimab versus 14 months for chemotherapy.The primary analysis, conducted in April, had shown a positive trend in overall survival but did not meet statistical significance. The company noted that&nbsp;the median follow-up for Western patients was shorter than their median overall survival at that time.Earlier results had already&nbsp;demonstrated that the trial met its main goal. Patients on ivonescimab plus chemotherapy were 48% less likely to see their cancer worsen or to die compared with those on chemotherapy alone.The treatment also produced better responses: 45% of patients saw their tumors shrink versus 34% on chemotherapy, and those responses lasted longer, with a median of 7.6 months compared with 4.2 months.Safety data showed the combination was generally manageable and consistent with prior studies.&nbsp;Grade 3 or higher treatment-related adverse events occurred in 50% of ivonescimab patients versus 42.2% in the chemotherapy arm. Discontinuations due to adverse events were 7.3% versus 5%, and treatment-related deaths were reported in 1.8% and 2.3% of patients, respectively. The most common events were anemia and reduced blood counts, with less than 1% of ivonescimab patients experiencing severe hemorrhage.Ivonescimab, also known as SMT112 outside China, is a first-in-class bispecific antibody targeting both PD-1 and Vascular Endothelial Growth Factor (VEGF).&nbsp;It was engineered by China’s Akeso and has been tested in more than 2,800 patients globally. The drug is already approved in China and has&nbsp;a U.S. FDA Fast Track designation in the HARMONi trial setting.On Stocktwits, retail sentiment for Summit was ‘extremely bullish’ amid ‘extremely high’ message volume.One retail user said that long-term investors in Summit had grown used to the stock falling even on positive news, but pointed out shares are still up nearly 700% over the past five years.<stembedurl>https://stocktwits.com/EB2224/message/627780145</stembedurl>Another user noted that while the day had been volatile, “the markets don’t lie” and suggested Summit CEO Robert Duggan might have more to reveal, adding that he has a reputation for frustrating short sellers. The user speculated the stock could hit $30 by the end of the day.<stembedurl>https://stocktwits.com/BooEmmy/message/627780010</stembedurl><a href="https://stocktwits.com/symbol/SMMT">Summit’s stock</a> has risen 45.6% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

 Summit’s stock (SMMT) has risen 45.6% so far in 2025. (Photo credit: Getty Images)

Retail Traders Flock To Summit Therapeutics After New Cancer Drug Data Shows Survival Gains

The updated Phase III HARMONi trial showed Western patients on ivonescimab lived a median 17 months versus 14 months on chemotherapy.

Summit Therapeutics (SMMT) shares were in the spotlight on Thursday after Guggenheim initiated coverage of the stock with a ‘Buy’ rating and a $40 price target.The price target represents a 70% upside from the stock’s closing price on Wednesday. SMMT stock has had a good run over the past year, nearly doubling in value.Guggenheim said that it liked Summit at $3 when the market was overlooking imminent data comparing progression-free survival with Summit’s Ivonescimab versus Merck's (MRK) blockbuster drug Pembrolizumab in lung cancer. Notably, the analyst said that they still like the stock at $24.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/SMMT">SMMT stock</a> fell from ‘bullish’ to ‘neutral’ territory over the past 24 hours, &nbsp;while message volume stayed at ‘low’ levels.<figure class="image"><img style="aspect-ratio:585/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_04_at_11_41_23_AM_png_000895180e.webp" alt="SMMT's Sentiment Meter and Message Volume as of 11:41 a.m. ET on Sept. 4, 2025 | Source: Stocktwits" width="585" height="62"><figcaption>SMMT's Sentiment Meter and Message Volume as of 11:41 a.m. ET on Sept. 4, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user said they see sustained growth potential for the stock.<stembedurl>https://stocktwits.com/db59/message/627464707</stembedurl>Guggenheim stated that if Summit's two late-stage clinical trials, HARMONi-3 and HARMONi-7, evaluating Ivonescimab in non-small cell lung cancer (NSCLC) are successful on progression-free survival or overall survival endpoints in 2027-2028, it has high conviction that the stock still has multi-fold upside potential from today's near-$20 billion valuation.While progression-free survival (PFS) is the length of time a patient with a disease, such as cancer, lives with the disease without it getting worse, or dies, overall survival (OS) is the total length of time a patient lives from the point of diagnosis or the start of treatment until death.HARMONi-3 is intended to evaluate Ivonescimab combined with chemotherapy compared to Pembrolizumab combined with chemotherapy in patients with first-line metastatic, squamous and non-squamous NSCLC. HARMONi-7 is intended to evaluate Ivonescimab monotherapy compared to Pembrolizumab monotherapy in patients with first-line metastatic NSCLC whose tumors produce a high amount of the PD-L1 protein.SMMT stock is up 32% this year and approximately 96% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/agios-pharma-stock-slumps-but-company-remains-top-pick-for-analyst/chwdJJlRdYs">Agios Pharma Stock Slumped 15% Today But Company Remains Top Pick For This Analyst – Find Out More</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Summit Therapeutics company logo is seen on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Summit Therapeutics Gets A $40 Price Target From Guggenheim: Analyst Says It Likes The Stock At $24, Just Like It Did At $3

The price target of $40 represents an upside of 70% from the stock’s closing price on Wednesday.

Summit Therapeutics drew heavy retail interest on Tuesday after its partner, Akeso, reported that ivonescimab (AK112), a closely watched lung cancer drug, helped patients live longer in a key late-stage trial.Akeso said the final analysis of the Phase III study in patients with EGFR-mutated, advanced non-squamous non-small cell lung cancer who had already failed EGFR-TKI therapy showed ivonescimab extended overall survival, meeting the trial’s main goal with a clear and meaningful benefit.&nbsp;Detailed data will be presented at an upcoming medical conference.The update came alongside Akeso’s first-half earnings and drove its Hong Kong-listed shares up as much as 5.92% on Wednesday. Meanwhile, Summit, which holds U.S. rights to ivonescimab, rose as much as 14% Tuesday on the news.&nbsp;While the drug is already approved in China, Summit is running a similar trial with a broader, global population to pave the way for an approval in the U.S.Ivonescimab has already won two approved indications in China: for EGFR-mutated NSCLC after EGFR-TKI therapy, and as monotherapy for PD-L1-positive advanced NSCLC.&nbsp;The drug has been included in clinical treatment guidelines, and Akeso has launched over 30 trials, including 13 Phase III studies and six head-to-head comparisons with PD-(L)1 therapies.Bernstein analysts led by Rebecca Liang called the survival data “a positive surprise,” noting that whether the drug could extend overall survival “has been the center of debate for AK112 since last year,” Bloomberg&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2025-08-27/akeso-s-lung-cancer-drug-hits-key-goal-in-china-study">reported</a>.&nbsp;They added it could be the biggest positive catalyst for Akeso since the company announced ivonescimab had outperformed Merck &amp; Co.’s top-selling cancer drug in a separate trial.On Stocktwits, retail sentiment was ‘extremely bullish’ for Summit Therapeutics amid ‘extremely high’ message volume, while Akeso drew ‘bullish’ sentiment with ‘high’ activity.One user speculated that Summit shares could reach $35 by&nbsp;the end of the week.&nbsp;<stembedurl>https://stocktwits.com/___dog___/message/626653621</stembedurl>Another suggested the stock was still digesting the overall survival news and argued it should already be trading above $30.<stembedurl>https://stocktwits.com/BooEmmy/message/626614344</stembedurl>While&nbsp;<a href="https://stocktwits.com/symbol/SMMT">Summit’s stock</a> has risen 51.2% so far in 2025,&nbsp;<a href="https://stocktwits.com/symbol/AKESF">Akeso’s U.S.-listed shares</a> have more than tripled over the same period.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

This Image Is A Part Of A Series On Pulmonary Pathologies. (Photo By BSIP/UIG Via Getty Images)

Summit Draws Frenzied Retail Chatter After Akeso Drug Shows Survival Benefit In Lung Cancer; Retail Sees More Upside

Analysts at Bernstein called the survival data “a positive surprise,” framing it as Akeso’s biggest catalyst since the drug previously outperformed Merck’s top-selling cancer therapy.

Can Keytruda Sustain Merck's Growth Through the Rest of 2025?

MRK banks on Keytruda's soaring sales and new oncology strategies to fuel 2025 growth, even as competition and patent loss loom.

SMMT Q2 Loss Wider Than Expected, Ivonescimab Studies in Focus

Summit Therapeutics posts wider-than-expected second-quarter loss as ivonescimab trials advance in multiple lung cancer settings.

Merck Stock Down 4% Since Q2 Results: How to Play the Stock

Merck slips following its Q2 results as Gardasil sales slump. However, Keytruda, new launches and a rich pipeline bolster its long-term case.

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

Will PepsiCo ($PEP) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

PepsiCo Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

SMMT
Summit Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest SMMT News

SMMT Summit Therapeutics Inc